Molecular data
| Molecular formula | C55H89N19O20 |
|---|---|
| Molecular weight | 1257.3 Da |
| Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| Sequence length | 11 residues |
| CAS / identifier | 1208243-50-8 |
| Physical form | Lyophilized powder |
| Available sizes | 10mg |
How it works
IRR (EPOR/CD131) Agonism
ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from the helix-B surface of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR) — a heterocomplex of the EPO receptor and the β-common receptor (CD131) — without engaging the classical receptor that drives red-cell production.
- Selective IRR (EPOR/βcR) agonism
- Non-erythropoietic — no effect on hematocrit
- Derived from EPO's helix-B surface domain
Resolution of Inflammation
Through the innate repair receptor, lower pro-inflammatory signalling and markers of its resolution have been measured, alongside reduced collateral tissue damage in the same models.
- Suppresses pro-inflammatory cytokine signaling
- Shifts macrophages toward a reparative phenotype
- Suppresses spinal microglial activation in pain models
Cytoprotective & Neural Signalling
IRR activation engages JAK2/STAT3, PI3K/Akt and anti-apoptotic Bcl-2-family pathways, with cell survival and small-fibre measures recorded despite the peptide's very short plasma half-life.
- Activates JAK2/STAT3 & PI3K/Akt survival signaling
- Anti-apoptotic Bcl-2 family engagement
- Small-fibre density measured in research models
What the research shows
Sarcoidosis Small-Fiber Neuropathy
ARA 290 is studied in small-fiber neuropathy models, including neuropathic symptom scores and physical-function measures in sarcoidosis research.
Corneal & Skin Nerve Fibre Density
Over a 28-day exposure, neuropathic symptom scores and small-fibre measures were recorded, including corneal nerve fibre density.
Long-Term Allodynia Relief
In rodent models, mechanical and cold allodynia thresholds were recorded over 20 weeks alongside spinal microglia response, with a dose-dependent relationship reported.
EPO-Derived Cytoprotection
ARA 290 was engineered from EPO's tertiary structure to engage the innate repair receptor selectively, without the erythropoietic activity of native EPO.
Specification
| Chemical Name | ARA-290 (Cibinetide) |
|---|---|
| Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11 aa) |
| Molecular Weight | 1,257.3 Da |
| Molecular Formula | C₅₅H₈₉N₁₉O₂₀ |
| CAS Number | 1208243-50-8 |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Sterile or bacteriostatic water |
| COA | Included with every order |
Frequently asked questions
What is ARA-290 and where does it come from?
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide engineered from the helix-B surface domain of erythropoietin (EPO). It was designed to engage the innate repair receptor selectively — without the red-blood-cell-stimulating activity of native EPO.
What is the innate repair receptor (IRR)?
The IRR is a heterocomplex of the EPO receptor and the β-common receptor (CD131). It is the arm of EPO signalling distinct from the classical homodimeric EPO receptor that controls erythropoiesis. ARA-290 selectively activates it.
Does ARA-290 raise red blood cell counts like EPO?
No. ARA-290 is non-erythropoietic — it does not engage the receptor pathway that drives red-cell production, so it does not raise hematocrit. That receptor separation is the central rationale behind its design.
What is ARA 290 studied for?
ARA 290 is studied in models of small-fiber neuropathy, where the measures examined include neuropathic symptom scores, corneal nerve fiber density and small nerve fiber regrowth. Preclinical models also examine long-term neuropathic pain behaviors.
Is this product intended for human use?
No. Research-grade ARA-290 sold here is strictly for in vitro laboratory research and analytical applications. It is not a drug and is not intended for human or veterinary use, consumption, or any clinical application.
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.